Health

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:…

4 months ago

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine…

4 months ago

Defeating the “Cold Chain” Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield Technology

SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a leader in expanding…

4 months ago

HCW Biologics Announces Pricing of $1.5 Million Follow-On OfferingPriced At-The-Market Under NASDAQ Rules

MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company…

4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 17, 2026 18:22 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio…

4 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as…

4 months ago

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD HEIDELBERG, Germany,…

4 months ago

Inventiva reports preliminary 2025 fiscal year financial results

Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5…

4 months ago

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in…

4 months ago

Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470

Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470U.S. NDA submission on track for…

4 months ago